Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. announced the conversion of a portion of its Tranche A Bonds, valued at US$10,000,000, at a conversion price of HK$3.672 per share. This move is part of the company’s ongoing financial management and compliance with regulatory requirements, aiming to maintain transparency and equal information dissemination among investors.
The most recent analyst rating on (HK:2186) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company is listed on the Hong Kong Stock Exchange and is involved in the issuance of convertible bonds as part of its financial strategies.
Average Trading Volume: 104,058,469
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.89B
For a thorough assessment of 2186 stock, go to TipRanks’ Stock Analysis page.